[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100283048":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":17,"responsibleParty":36,"collaborators":7,"id":38,"slug":7,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":7,"eligibilityCriteria":42,"healthyVolunteers":43,"sex":44,"minAge":7,"maxAge":7,"enrollmentInfo":45,"targetDuration":48,"studyType":49,"phases":7,"briefSummary":50,"conditions":51,"keywords":7,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},{"fullName":5,"class":6},"Children's Hospital Medical Center, Cincinnati","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Theodosia Kalfa, MD, PhD","PRINCIPAL_INVESTIGATOR",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":7},"Hotline","CONTACT","513-636-6770",[18],{"facility":19,"status":20,"city":21,"state":22,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"Cincinnati Children's Hospital Medical Center","RECRUITING","Cincinnati","Ohio","45229","United States","US",{"type":27,"coordinates":28},"Point",[29,30],-84.51439,39.12711,{"lat":30,"lon":29},[33,35],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":34},"theodosia.kalfa@cchmc.org",{"name":10,"role":11,"phone":7,"phoneExt":7,"email":7},{"type":37,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100283048",false,"NCT02964494","The Congenital Dyserythropoietic Anemia Registry (CDAR)","Inclusion Criteria:\n\n* Diagnosis of Congenital Dyserythropoietic Anemia (CDA), whether a genetic mutation is identified or not\n* Evidence of congenital anemia\u002Fjaundice or a positive family history\n* Evidence of ineffective erythropoiesis\n* Typical morphological appearance of bone marrow erythroblasts\n* All ages (ages 0-99)\n\nExclusion Criteria:\n\n* Diagnosis of cancer\n* Myelodysplasia\n* Secondary dyserythropoiesis: e.g.; vitamin B12 deficiency or drug-related.\n\nNote1: Patients with rare band 3 (SLC4A1) mutations recently described to be associated with dyserythropoiesis will be eligible since the mechanisms appear to involve direct participation of band 3 in the erythroblast mitosis and cytokinesis.\n\nNote2: Siblings, parents, and family members of patients with confirmed CDA diagnosis are encouraged to participate in the study.",true,"ALL",{"count":46,"type":47},10000,"ESTIMATED","15 Years","OBSERVATIONAL","The investigators have created and maintain a comprehensive registry for patients with the diagnosis of Congenital Dyserythropoietic Anemia (CDA) in North America. The goal of this registry is to collect long-term confidential data on patients with CDA in the US, Canada, and Mexico and maintain a bio-repository of de-identified patient blood and bone marrow specimens as a tool for the investigation of epidemiology, natural history, biology, and molecular pathogenetic mechanisms of CDA.",[52],"Congenital Dyserythropoietic Anemia (CDA)","2026-06-15",{"date":55,"type":56},"2026-06-16","ACTUAL",{"date":58,"type":56},"2016-08-29",{"date":60,"type":47},"2031-01",{"name":5,"class":6},1]